Incorrect password
evipedia.ai Suggest Edit

Tribulus terrestris for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Tribulus, Puncture Vine, Gokshura, Goat’s Head, Caltrop, Bindii, Ci Ji Li

Motivation

Tribulus terrestris is a flowering plant whose fruits and roots have been used for centuries in Ayurvedic medicine (Gokshura) and Traditional Chinese Medicine, primarily for sexual and reproductive health. Its proposed primary mechanism involves the release of nitric oxide, a signaling molecule that relaxes blood vessels.

Modern interest centers on the supplement’s reputation as a “natural testosterone booster” — a claim that drove its adoption in sports nutrition and male enhancement markets after Eastern European athletes used standardized extracts in the 1990s. The contemporary picture is more nuanced: the testosterone-elevation claim is no longer well supported in men with normal hormone levels, while a separate sexual-function signal has been replicated across controlled trials in both sexes.

This review examines the available human evidence on Tribulus terrestris — its documented effects on sexual function, its safety profile including rare cases of organ toxicity, drug-interaction concerns, and the quality issues affecting commercially available products.

Benefits - Risks - Protocol - Conclusion

A curated selection of resources providing accessible, high-level overviews of Tribulus terrestris, its mechanisms, and its clinical evidence.

  • The Science of Love, Desire and Attachment - Andrew Huberman

    Huberman Lab Podcast Episode #59 includes a discussion of Tribulus terrestris and its effects on libido — particularly in women — with analysis of the dose ranges used in peer-reviewed studies and the mechanistic basis for its sexual-function effects.

  • How To Increase Your Testosterone Levels Naturally — Derek from MPMD - Rhonda Patrick

    FoundMyFitness Episode #106 with Derek (More Plates More Dates) examines Tribulus terrestris alongside other commonly marketed testosterone-supporting supplements, distinguishing evidence-based effects from overhyped marketing claims in a long-form expert conversation.

  • Male Hormone Restoration - Sandhaus & Decker

    Life Extension’s protocol places Tribulus terrestris in the broader context of male hormonal health, discussing its principal saponin protodioscin, its proposed effects on libido and erectile function, and practical dosing drawn from the clinical trial literature.

  • Does Tribulus Terrestris Really Work? An Evidence-Based Look - Grant Tinsley

    A balanced, evidence-based overview that walks through the published claims for testosterone, blood sugar, cholesterol, and sexual function, concluding that the testosterone-boosting reputation is not supported by controlled human trials while sexual function effects are more defensible.

  • A Comprehensive Review of the Phytochemical, Pharmacological, and Toxicological Properties of Tribulus terrestris L. - Ștefănescu et al., 2020

    A thorough academic narrative review covering the saponin and flavonoid chemistry of the plant, its proposed pharmacological mechanisms across multiple organ systems, and the toxicological signal from case reports — useful background on why the safety questions persist despite the popularity of the supplement.

No directly relevant standalone content discussing Tribulus terrestris was found from Peter Attia or Chris Kresser, which is why an academic narrative review and an evidence-based independent overview complete the list rather than additional priority-expert podcasts or articles.

Grokipedia

Goat’s Head

The Grokipedia article on Tribulus terrestris (filed under its common name “Goat’s head”) covers the plant’s taxonomy, geographic distribution, invasive ecology, and ethnopharmacological use, including its steroidal-saponin chemistry and the traditional indications across Ayurvedic and Mediterranean medical systems.

Examine

Tribulus terrestris benefits, dosage, and side effects

The Examine.com supplement page provides an evidence-graded overview of Tribulus terrestris effects on sexual function, testosterone, lipid profile, and inflammatory markers, drawing on meta-analyses and the available randomized trials and grading the quality of evidence behind each outcome.

ConsumerLab

No standalone ConsumerLab article on Tribulus terrestris was found.

Systematic Reviews

A summary of systematic reviews and meta-analyses evaluating Tribulus terrestris supplementation, drawn from PubMed.

Mechanism of Action

Tribulus terrestris exerts its biological effects through a complex mixture of constituents, with steroidal saponins — particularly protodioscin and related furostanol/spirostanol glycosides — considered the principal bioactives. Flavonoids (kaempferol, quercetin glycosides), alkaloids (harman, harmine), and lignans contribute additional activity.

The most consistently supported mechanism involves the nitric oxide pathway. Protodioscin promotes the release of nitric oxide (NO, a gas that signals blood vessels to relax) from vascular endothelium (the inner lining of blood vessels), particularly in the corpus cavernosum (the erectile tissue of the penis). The resulting smooth-muscle relaxation increases cavernous blood flow and intracavernous pressure, providing a plausible explanation for the observed effects on erectile function that does not depend on changes in circulating testosterone.

The proposed androgen-related mechanism remains contentious. Animal studies and a small number of trials in hypogonadal (low-testosterone) men have reported increases in testosterone, dihydrotestosterone, and DHEA (dehydroepiandrosterone, a steroid precursor produced by the adrenal glands), suggesting possible upstream stimulation of the hypothalamic-pituitary-gonadal axis or weak androgen-receptor binding by saponin aglycones. Competing mechanistic interpretations point to the consistent failure to detect testosterone changes in eugonadal (normal-testosterone) men across modern RCTs as evidence that any hormonal effect is restricted to deficient states or absent altogether and that earlier reports may have reflected methodological artifact.

Anti-inflammatory and antioxidant activity is well documented in preclinical models. Saponin and flavonoid fractions reduce pro-inflammatory cytokines, downregulate NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a master transcription factor controlling inflammation) signaling, scavenge reactive oxygen species, and upregulate endogenous antioxidant enzymes such as superoxide dismutase and catalase. Whether these in vitro effects translate to systemic anti-inflammatory benefit at oral supplement doses is uncertain.

Effects on lipid and glucose metabolism appear to involve modulation of intestinal cholesterol absorption, partial inhibition of α-glucosidase (an intestinal enzyme that breaks down complex carbohydrates), and possible insulin-sensitizing effects mediated by adipose-tissue and liver pathways. The molecular details remain incompletely characterized.

Pharmacological properties: Tribulus terrestris extracts are mixtures rather than single chemical entities, which complicates pharmacokinetic description. Saponin content of standardized extracts ranges from 45–60% (sometimes up to 95% in concentrated preparations). Plasma half-life of protodioscin and its sapogenins has not been definitively characterized in humans; the use of 2–3 daily divided doses in clinical trials suggests a relatively short effective duration. Metabolism is presumed to involve hepatic cytochrome P450 (CYP) enzymes — relevant in vitro data show inhibition of CYP3A4 (cytochrome P450 3A4, a major liver enzyme metabolizing approximately half of all prescription drugs) — and intestinal saponin hydrolysis to active sapogenins. Tissue distribution is not well defined; central-nervous-system penetration appears limited based on preclinical data.

Historical Context & Evolution

Tribulus terrestris has a long ethnomedical history across multiple geographies. In Ayurvedic medicine the fruit is known as Gokshura and has been used for centuries to treat urinary disorders, kidney stones, and as a general rasayana (rejuvenative tonic) supporting vitality. In Traditional Chinese Medicine the fruit (Ci Ji Li, sometimes Bai Ji Li) has been employed for headache, ophthalmic complaints, vertigo, and as a liver-pacifying agent. In Greek and Middle Eastern systems it served as a diuretic and aphrodisiac; the genus name derives from Latin tribulus — itself from Greek τρίβολος — for the spiked weapon (the caltrop) that resembles the plant’s fruit.

The pivotal modern development came in the 1970s and 1980s, when researchers at the Chemical Pharmaceutical Research Institute in Sofia, Bulgaria — later commercialized as Sopharma, the manufacturer that derives direct revenue from Tribestan sales — characterized a standardized fruit extract under the trademark Tribestan, attributing aphrodisiac and ergogenic activity to its steroidal-saponin content. Bulgarian Olympic weightlifters were reported to have used the extract in the 1980s, and after the fall of the Eastern Bloc the product spread into Western sports-nutrition markets. The marketing claim that Tribulus terrestris raises testosterone — anchored in early animal data and intuitive mapping from “saponin steroidal scaffold” to “anabolic effect” — drove rapid commercial growth through the 1990s.

The actual research findings tell a more measured story. Early clinical trials from Bulgarian groups reported testosterone increases, but these studies were typically small, open-label, and methodologically heterogeneous. Successive double-blind, placebo-controlled trials in eugonadal men — including a Neychev and Mitev (2005) study in young men and a Saudan et al. (2008) study in elite athletes — found no testosterone effect. By the late 2010s the accumulated meta-analytic evidence consistently failed to support the testosterone-boosting claim, while a separate body of work emerged showing genuine effects on sexual function in both men with erectile dysfunction and women with sexual dysfunction.

The evolution of scientific opinion reflects a real shift rather than a settled consensus. Mainstream sports-medicine bodies have downgraded Tribulus terrestris as an ergogenic aid, while sexual-medicine literature has cautiously accepted a non-hormonal benefit on erectile function and on female sexual function. Older claims rooted in Eastern European tradition are not “debunked” so much as reframed: the underlying biochemistry remains active and the sexual-function signal has been confirmed, but the testosterone-elevation claim is not supported by modern controlled trials. Both the early enthusiasm and the later dismissal reflect partial truths; the contemporary evidence supports a narrower but real role.

Expected Benefits

A dedicated search was performed across PubMed, Examine, FoundMyFitness, ConsumerLab, Life Extension, drugs.com, and Memorial Sloan Kettering’s About Herbs database to ensure the benefit profile below covers the full landscape of claimed effects.

Medium 🟩 🟩

Improved Erectile Function

Multiple RCTs and a 2026 meta-analysis (Suharyani et al., 8 trials) demonstrate that Tribulus terrestris supplementation significantly improves erectile function scores on the IIEF-5 and IIEF-15 (the 5-item and 15-item versions of the International Index of Erectile Function questionnaire) compared to placebo in men with mild-to-moderate erectile dysfunction. The mechanism appears to be nitric-oxide-mediated vasodilation rather than testosterone elevation, since hormone levels typically remain unchanged. Effects were most consistent at 750–1,500 mg/day of standardized extract for 8–12 weeks. Vilar Neto et al. (2025) graded the overall body of evidence as low-quality because of small sample sizes and heterogeneous formulations across trials.

Magnitude: IIEF-5 improvement of approximately 3.2 points over placebo (95% CI — 95% confidence interval, the range within which the true effect is expected to fall: 1.89–4.58); IIEF-15 improvement of approximately 14 points over placebo at 750–1,500 mg/day for 8–12 weeks.

Improved Female Sexual Function

A 2020 systematic review (Martimbianco et al., 5 RCTs, 279 women) found that Tribulus terrestris significantly improved overall sexual function scores (FSFI, Female Sexual Function Index — a validated multi-domain questionnaire) compared to placebo in both premenopausal and postmenopausal women. Effects were observed for desire, arousal, lubrication, and orgasm domains over 1–4 month trials at doses of 250–750 mg/day. The certainty of evidence was rated very low by the systematic review authors due to small samples, but the direction and consistency of effect are supportive. Some authors have hypothesized a small testosterone increase contributes in postmenopausal women specifically, but the primary mechanism is more likely the same nitric-oxide-mediated vasodilation that operates in men.

Magnitude: Standardized mean differences (SMD, a way of expressing effect size in standard-deviation units when different scales are pooled) above 1.0 for overall sexual function, desire, and arousal; SMD around 0.5 for orgasm domain. Doses of 250–750 mg/day for 1–4 months.

Low 🟩

Improved Lipid Profile

The Fernández-Lázaro et al. (2022) systematic review in physically active males reported significant improvements in lipid profile with Tribulus terrestris supplementation. A separate RCT in women with type 2 diabetes (a chronic condition characterized by elevated blood sugar due to insulin resistance) showed significant reductions in total cholesterol and LDL (low-density lipoprotein, often called “bad cholesterol”) after 3 months of 1,000 mg/day, with no significant effect on triglycerides or HDL (high-density lipoprotein, often called “good cholesterol”). The magnitude in healthy populations remains poorly quantified.

Magnitude: Statistically significant reductions in total cholesterol and LDL in diabetic and physically active populations; effect size in healthy adults not well quantified.

Improved Glycemic Control ⚠️ Conflicted

A double-blind RCT in 98 women with type 2 diabetes (Samani et al., 2016) demonstrated that 1,000 mg/day of Tribulus terrestris extract for 3 months significantly reduced fasting blood glucose, 2-hour postprandial (after-meal) glucose, and HbA1c (glycated hemoglobin, a marker of average blood sugar over the prior 2–3 months) compared to placebo. However, several other small trials in non-diabetic or pre-diabetic populations have failed to detect glycemic effects, and the mechanism through α-glucosidase inhibition has not been confirmed in human pharmacokinetic studies. The conflict appears to be driven by baseline glycemic status: clear benefit in overt type 2 diabetes, no detectable effect in metabolically healthy adults.

Magnitude: Significant reductions in fasting glucose, postprandial glucose, and HbA1c in diabetic women at 1,000 mg/day for 3 months; no consistent effect in non-diabetic populations.

Improved Sperm Parameters

A 2019 systematic review of 7 studies in men with idiopathic infertility found that 6 of 7 trials reported improvements in sperm count, motility, or morphology following Tribulus terrestris supplementation, typically at 750–1,500 mg/day for 60–90 days. Methodological quality varied considerably, and head-to-head data against established fertility interventions are lacking. The mechanism may involve antioxidant protection of sperm, improved testicular blood flow via nitric oxide, or modest increases in luteinizing hormone reported in some trials.

Magnitude: Reported improvements in sperm count, motility, and morphology in 6 of 7 trials at 750–1,500 mg/day for 60–90 days; absolute changes not consistently quantified across studies.

Anti-Inflammatory Effects

The Fernández-Lázaro et al. (2022) review noted moderate beneficial effects on inflammatory biomarkers in physically active adult males. Preclinical work consistently demonstrates reductions in pro-inflammatory cytokines (TNF-α — tumor necrosis factor alpha, a key pro-inflammatory cytokine; IL-6 — interleukin-6) and downregulation of NF-κB signaling in a range of challenge models. Human evidence is limited to changes in surrogate biomarkers rather than clinically meaningful endpoints.

Magnitude: Not quantified in available studies.

Speculative 🟨

Antioxidant and Neuroprotective Effects

Animal studies suggest Tribulus terrestris methanolic and ethanolic extracts may improve memory and reduce oxidative stress markers in rodent models of cognitive impairment, with doses of 100–1,000 mg/kg (rodent equivalent) producing significant neuroprotection. A specific compound — tribulusterine — has shown preclinical attenuation of stress-kinase-mediated neuroinflammation. No adequately powered human clinical trials of Tribulus terrestris for cognitive endpoints have been published; the basis for this entry is mechanistic and animal data only.

Cardioprotective Effects

Preclinical evidence indicates potential cardioprotective activity through protection of myocardial cells from ischemia/reperfusion injury and reduction in oxidative-stress-induced apoptosis (programmed cell death). The blood-pressure and lipid-modulating effects observed clinically would, if real and durable, provide indirect cardiovascular benefit. However, no dedicated human cardiovascular outcome trials have been conducted; the basis for this entry is animal data and mechanistic extrapolation from surrogate endpoints.

Anti-Urolithic (Kidney Stone) Effects

Traditional use as Gokshura for urinary disorders is supported by preclinical evidence of diuretic and anti-urolithic (kidney-stone-preventing) properties, with rodent models showing reduced calcium oxalate crystal deposition. No rigorous human RCT data exist; the basis is traditional use and animal models.

Reduced Climacteric Symptoms in Postmenopausal Women

Small trials in postmenopausal women have reported modest improvements in vasomotor (hot flushes, night sweats), psychological, and somatic complaints with Tribulus terrestris, possibly mediated by mild estrogenic or androgenic activity of saponin aglycones. The evidence base is limited to a handful of small studies; the basis is preliminary clinical signal alongside mechanistic plausibility.

Benefit-Modifying Factors

  • Baseline hormonal status: The limited evidence for testosterone increase has appeared only in hypogonadal men (those with clinically low baseline testosterone). Eugonadal men consistently show no hormonal response across modern controlled trials. Postmenopausal women with low free testosterone may experience small hormonal effects that do not occur in younger women.

  • Sex-based differences: Women — particularly postmenopausal women — appear more responsive to the sexual-function effects than men in side-by-side comparison, with larger effect sizes for desire and arousal domains. Erectile-function benefit in men is the more robust and reproducible signal in absolute terms.

  • Baseline metabolic status: Glycemic and lipid benefits have been demonstrated primarily in adults with overt type 2 diabetes or dyslipidemia (abnormal blood lipid levels). Whether similar effects occur in metabolically healthy adults is not established.

  • Pre-existing health conditions: Men with diagnosed mild-to-moderate erectile dysfunction show the clearest benefit. Adults with idiopathic infertility may experience improvements in sperm parameters. Adults without these conditions are unlikely to perceive a clinical effect.

  • Age: Trials in older men with erectile dysfunction (typically 250 mg three times daily for 3 months) have shown positive effects; younger, healthy male athletes generally show no hormonal or performance benefit. Postmenopausal women appear more responsive than premenopausal women to the sexual-function effects.

  • Saponin content and source: The biological activity of Tribulus terrestris products varies substantially with saponin concentration (typically 45–60% in standardized extracts, up to 95% in concentrated preparations), the plant part used (fruit vs. root vs. aerial parts), the geographic source (Bulgarian, Turkish, and Indian sources are traditionally credited with higher protodioscin content), and the extraction solvent. Non-standardized products may show no effect even at apparently equivalent doses.

  • Genetic polymorphisms: No specific pharmacogenomic variants have been identified that modify Tribulus terrestris response in clinical trials. Variants affecting CYP3A4 activity could theoretically influence saponin metabolism and the magnitude of any drug-interaction effect, but this has not been characterized in human studies.

Potential Risks & Side Effects

Medium 🟥 🟥

Gastrointestinal Disturbances

Gastrointestinal symptoms — nausea, stomach cramps, dyspepsia (indigestion or upper-abdominal discomfort), and loose stools — are the most commonly reported adverse effects in clinical trials and are attributed to the saponin content, which is intrinsically irritating to mucosal surfaces at higher concentrations. These effects are generally mild, dose-dependent, and reversible on discontinuation. The incidence in controlled trials is typically not significantly different from placebo at standard doses, but rises with doses above 1,000 mg/day or when taken on an empty stomach.

Magnitude: Mild-to-moderate symptoms in a minority of users; incidence comparable to placebo at standard doses (250–750 mg/day) in most trials, increasing at doses above 1,000 mg/day.

Low 🟥

Hepatotoxicity

Case reports document rare but potentially severe hepatotoxicity (drug-induced liver injury) associated with Tribulus terrestris supplementation. A widely cited case described a 28-year-old man who developed cholestatic hepatitis (liver injury characterized by impaired bile flow) with peak total bilirubin around 48 mg/dL after taking an oral Tribulus terrestris product for two months. The NCBI LiverTox monograph notes that while Tribulus has been linked to fatal cholestatic hepatic injury in livestock that consume the plant in pasture, isolated human cases of clinically apparent liver injury have been reported. Most trials have shown no measurable change in liver enzymes at standard doses, but the case-report signal warrants attention.

Magnitude: Rare (isolated case reports across the published literature); when it occurs, severity can be high, with bilirubin elevations to greater than 40 mg/dL described.

Nephrotoxicity

A small number of published cases have reported acute kidney injury in association with Tribulus terrestris, sometimes alongside hepatic injury. One published case described severe nephrotoxicity (kidney damage) in a young, previously healthy man, with serum creatinine (a waste product cleared by the kidneys, elevated when kidney function is impaired) rising above 7 mg/dL in the context of concurrent hepatic injury.

Magnitude: Rare (isolated case reports); when present, can be severe enough to require hospitalization.

Drug Interactions via CYP3A4 Inhibition

In vitro and limited human pharmacokinetic data suggest Tribulus terrestris moderately inhibits CYP3A4. A documented case of rhabdomyolysis (severe muscle breakdown that can release myoglobin and damage kidneys) was reported in a man who combined Tribulus terrestris with atorvastatin (a CYP3A4-metabolized statin), with the interaction implicated through toxic statin accumulation. Similar interactions are theoretically possible across the broad set of CYP3A4 substrate medications.

Magnitude: Clinically significant when combined with narrow-therapeutic-index CYP3A4 substrates (especially statins); rhabdomyolysis is a life-threatening adverse event when it occurs.

Additive Hypoglycemic Effect

Tribulus terrestris has been shown in trials in diabetic populations to lower blood glucose and HbA1c. When combined with insulin or insulin secretagogues such as sulfonylureas (a class of oral diabetes medications that stimulate pancreatic insulin release), this additive effect may produce clinically significant hypoglycemia (dangerously low blood sugar).

Magnitude: Not quantified in available studies.

Additive Hypotensive Effect

The supplement’s nitric-oxide-mediated vasodilation may modestly lower blood pressure on its own. When combined with antihypertensive medications or other vasodilator supplements, this effect can compound and produce orthostatic hypotension (a drop in blood pressure on standing that can cause dizziness or fainting), particularly in older adults whose baroreflex response is less robust. The evidence base is mechanistic and inferred from the same nitric oxide pathway implicated in the erectile-function effect, with no controlled trials specifically measuring blood-pressure interactions.

Magnitude: Not quantified in available studies.

Speculative 🟨

Possible Antiplatelet / Thrombotic Risk

A single case report described stent thrombosis (clot formation in a coronary stent) in a patient taking clopidogrel (an antiplatelet drug) concurrently with a multi-ingredient herbal preparation containing Tribulus terrestris. Causality is uncertain because of the mixed-ingredient context. The basis for this entry is the isolated case report and the mechanistic plausibility of platelet-function modulation by saponin compounds.

Sleep Disturbance and Cardiovascular Stimulation

Anecdotal user reports describe sleep disturbance, fatigue, and elevated resting heart rate at doses above 1,000 mg/day. These effects have not been systematically evaluated in controlled trials. The basis for this entry is anecdotal experience reports and the absence of contrary evidence at high-dose ranges.

Contamination with Undeclared Steroids

Independent testing has repeatedly identified Tribulus terrestris products — particularly those marketed for bodybuilding or male enhancement — that contain undeclared anabolic steroids, synthetic testosterone, prohormones, or PDE5 inhibitors (the drug class that includes sildenafil — a prescription drug for erectile dysfunction sold under the brand name Viagra). The basis for this entry is independent product-testing reports rather than randomized data, and the practical risk depends entirely on the product chosen.

Hormonal Disruption in Women of Reproductive Age

Animal studies have produced inconsistent signals on reproductive hormones, with some reports of disrupted estrous cycling at high doses. Human data in women of reproductive age are limited to short-duration sexual-function trials that did not systematically assess endocrine endpoints. The basis for this entry is preclinical signal and gaps in human data.

Risk-Modifying Factors

  • Pre-existing liver or kidney disease: Adults with chronic hepatitis, fatty liver disease, or chronic kidney disease may be at elevated risk for the rare but potentially severe organ toxicity reported in case reports. Baseline hepatic and renal function testing is sensible before initiation in any adult, and essential in those with prior abnormalities.

  • Concurrent statin use: The CYP3A4 inhibitory activity of Tribulus terrestris poses specific risk for adults taking statins primarily metabolized by CYP3A4 — atorvastatin, lovastatin, and simvastatin — through toxic statin accumulation potentially resulting in rhabdomyolysis. Pravastatin and rosuvastatin have less CYP3A4 dependence and are lower-risk in this context.

  • Diabetes medication use: Adults on insulin, sulfonylureas, meglitinides, or other agents with hypoglycemia potential face additive risk; dose adjustments may be needed under medical guidance.

  • Antihypertensive medication use: Concurrent use with antihypertensive drugs may produce excessive blood pressure lowering or orthostatic hypotension, particularly in older adults.

  • Pre-existing cardiovascular disease: Adults with severe aortic stenosis (a narrowing of the aortic valve where vasodilation can be poorly tolerated), recent myocardial infarction (heart attack within the past 90 days), or unstable angina should be cautious with any vasodilator; the limited data on Tribulus terrestris in these populations argue for avoidance until better evidence is available.

  • Sex-based differences: The bulk of safety data comes from male participants. Risk profile in women — particularly women of reproductive age — is less well characterized, and the limited reproductive-hormone signal in animal studies argues for additional caution in women planning pregnancy.

  • Age: Older adults face higher risk for drug interactions due to polypharmacy (taking multiple medications simultaneously) and for adverse outcomes from organ toxicity due to reduced hepatic and renal reserve. They are also the population most likely to derive benefit, requiring an individualized risk-benefit assessment.

  • Genetic polymorphisms: Adults with reduced CYP3A4 activity (poor or intermediate metabolizers) may experience altered exposure to both Tribulus terrestris saponins and co-administered CYP3A4 substrate medications, but this has not been specifically characterized in published studies and is not currently actionable in routine practice.

  • Baseline biomarker levels: Adults with already-elevated transaminases (ALT — alanine aminotransferase, AST — aspartate aminotransferase, both liver enzymes), elevated bilirubin, or reduced eGFR (estimated glomerular filtration rate, a calculated measure of kidney function) at baseline should weigh the risk-benefit balance more carefully.

Key Interactions & Contraindications

  • Statins, especially CYP3A4-metabolized statins (atorvastatin, lovastatin, simvastatin): Documented CYP3A4-mediated interaction leading to elevated statin levels and rhabdomyolysis case report. Severity: caution to avoid; clinical consequence: muscle injury and acute kidney injury from rhabdomyolysis. Mitigation: avoid combination, or substitute with a less CYP3A4-dependent statin (pravastatin, rosuvastatin) and monitor creatine kinase if combination is unavoidable.

  • Lithium: Tribulus terrestris has been reported to reduce lithium clearance, raising serum lithium concentrations. Severity: caution; clinical consequence: lithium toxicity (tremor, confusion, arrhythmia). Mitigation: avoid concurrent use, or monitor lithium levels closely.

  • Diabetes medications (insulin, sulfonylureas (a class of drugs that stimulate insulin release from the pancreas — glipizide, glyburide), metformin, SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors — empagliflozin, dapagliflozin)): Additive hypoglycemic effect. Severity: monitor; clinical consequence: hypoglycemia. Mitigation: monitor fingerstick glucose closely; consider downward dose adjustment of the diabetes medication under physician guidance.

  • Antihypertensive medications (ACE inhibitors (angiotensin-converting enzyme inhibitors — lisinopril, ramipril, a class of blood-pressure-lowering drugs), ARBs (angiotensin receptor blockers — losartan, valsartan, also blood-pressure-lowering), calcium channel blockers (amlodipine, diltiazem), beta-blockers (metoprolol, atenolol)): Additive blood-pressure-lowering effect. Severity: monitor; clinical consequence: hypotension or orthostatic hypotension. Mitigation: monitor home blood pressure during initiation; rise slowly from lying or seated positions in older adults.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel, aspirin): Possible interference with antiplatelet therapy based on a single case report. Severity: caution; clinical consequence: stent thrombosis or bleeding. Mitigation: discuss with a prescriber before combining; monitor INR (international normalized ratio, a measure of warfarin anticoagulation) more frequently if combining with warfarin.

  • CYP3A4 substrate drugs (in addition to statins; including ketoconazole, ritonavir, cyclosporine, tacrolimus): Possible elevated drug exposure due to CYP3A4 inhibition. Severity: caution; clinical consequence: increased adverse effects of the substrate drug. Mitigation: avoid combination with narrow-therapeutic-index CYP3A4 substrates such as cyclosporine and tacrolimus.

  • P-glycoprotein substrate drugs (digoxin, dabigatran, certain HIV protease inhibitors): Saponins and phenolic compounds in Tribulus terrestris can inhibit P-gp (P-glycoprotein, a cell-membrane efflux pump that exports drugs from cells), potentially increasing absorption of substrate drugs. Severity: monitor; clinical consequence: increased drug exposure. Mitigation: monitor for substrate-specific toxicity (e.g., digoxin levels).

  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs, such as ibuprofen and naproxen): Concurrent use may increase gastrointestinal mucosal irritation through additive saponin and NSAID effects, and may compound any blood-pressure-lowering effect at the level of renal prostaglandins. Severity: monitor; clinical consequence: gastrointestinal upset, modest blood-pressure changes. Mitigation: take with food; avoid chronic high-dose combination.

  • Other supplements with additive blood-sugar-lowering effects (berberine, chromium, alpha-lipoic acid, gymnema): Additive hypoglycemic effect. Severity: monitor; clinical consequence: hypoglycemia. Mitigation: stagger introduction; monitor glucose.

  • Other supplements with additive blood-pressure-lowering effects (magnesium, CoQ10 (coenzyme Q10, a mitochondrial electron carrier), garlic extract, beetroot/nitrate, hibiscus): Additive hypotensive effect. Severity: monitor; clinical consequence: hypotension. Mitigation: monitor home blood pressure when stacking.

  • Hormone-modulating supplements and therapies (DHEA, ashwagandha, fenugreek, hormone replacement therapy): Theoretical additive endocrine effect; data are insufficient to characterize the magnitude. Severity: caution; clinical consequence: unpredictable hormonal effects in sensitive individuals. Mitigation: stagger introduction of new hormone-modulating agents, monitor relevant hormone panels (testosterone, estradiol, DHEA-S — DHEA sulfate, the storage and circulating form of DHEA) periodically, and consult an endocrinologist or knowledgeable prescriber before stacking.

Populations who should avoid Tribulus terrestris:

  • Pregnant or breastfeeding women (insufficient safety data; theoretical hormonal effects)
  • Adults with active liver disease or unexplained transaminase elevations (ALT or AST > 2× upper limit of normal)
  • Adults with chronic kidney disease (eGFR < 60 mL/min/1.73 m²) or recent acute kidney injury
  • Adults receiving lithium therapy
  • Adults undergoing treatment for hormone-sensitive cancers (breast, prostate, ovarian) until further data clarify the endocrine signal
  • Adults scheduled for elective surgery within 14 days (discontinue at least 2 weeks prior because of potential antiplatelet, hypoglycemic, and hypotensive effects)
  • Children and adolescents under 18 (no safety data; theoretical concern about endocrine modulation during development)

Risk Mitigation Strategies

  • Baseline laboratory panel before initiation: Practitioner protocols typically include liver function tests (ALT — alanine aminotransferase, AST — aspartate aminotransferase, total bilirubin), kidney function (creatinine, BUN — blood urea nitrogen, eGFR), fasting glucose, HbA1c, and a lipid panel before starting. This mitigates the risk of initiating supplementation in the presence of undetected baseline organ dysfunction and provides a reference for detecting drug-induced injury.

  • Comprehensive medication review: Pharmacist- or prescriber-led review of statins (atorvastatin, lovastatin, simvastatin), lithium, diabetes medications, antihypertensives, anticoagulants, and other CYP3A4 substrates is part of conservative practitioner protocols. This mitigates the documented CYP3A4-statin interaction risk and the additive hypoglycemic and hypotensive risks.

  • Low starting dose with slow titration: Conservative protocols begin at 250–500 mg/day of a standardized extract (45–60% saponins) and titrate to the trial-supported range (typically 750 mg/day) over 2–4 weeks while tolerance is assessed. This mitigates gastrointestinal side effects and allows detection of unexpected hypotensive or hypoglycemic effects before scaling up.

  • Dosing with meals: Administration of doses with food substantially reduces gastrointestinal side effects and may improve absorption of saponins. This mitigates the most common adverse-effect category.

  • Ongoing liver and kidney function monitoring: Trial protocols repeat ALT, AST, total bilirubin, and creatinine at 4–6 weeks after starting, then every 3–6 months during continued use. This mitigates the risk of clinically silent early drug-induced organ injury.

  • Third-party-tested product selection: Products verified by NSF International (NSF Certified for Sport), USP (United States Pharmacopeia), or Informed Sport are favored, particularly by adults subject to anti-doping testing. This mitigates the well-documented contamination risk with undeclared steroids, prohormones, and PDE5 inhibitors.

  • Discontinuation at the first sign of organ injury: Practitioner protocols call for immediate discontinuation and medical evaluation in the presence of jaundice (yellowing of skin or eyes), dark urine, persistent right-upper-quadrant pain, unusual fatigue, decreased urine output, or lower-extremity swelling. This mitigates the potential for serious outcomes from the rare hepatotoxicity and nephrotoxicity case-report signal.

  • Home blood pressure monitoring during initiation: For adults already on antihypertensive medication or stacking blood-pressure-lowering supplements, blood pressure is typically measured daily for the first 2 weeks, then weekly through 8 weeks. This mitigates additive hypotension.

  • Closer glucose monitoring in diabetic adults: For adults on diabetes medication, fingerstick glucose monitoring is increased during the first month of use and diabetes medication doses are adjusted with the prescribing physician as needed. This mitigates additive hypoglycemia.

  • Limited continuous duration with reassessment at 3 months: Most clinical trials evaluated 1–3 month courses. Longer-term safety data are sparse, so practitioner protocols typically use a 3-month evaluation point with repeat labs as a precautionary checkpoint. This mitigates accumulation of any subclinical organ stress over prolonged exposure.

  • Discontinuation 14 days before elective surgery: Practitioner protocols call for stopping Tribulus terrestris at least 14 days before any planned surgical procedure to allow any antiplatelet, hypoglycemic, and hypotensive effects to wash out. This mitigates surgical bleeding, perioperative hypoglycemia, and intraoperative blood-pressure instability.

Therapeutic Protocol

The standard Tribulus terrestris protocol used by leading practitioners draws from the Eastern European sports-medicine tradition popularized by the Bulgarian Chemical Pharmaceutical Research Institute (now Sopharma — the commercial manufacturer of the Tribestan standardized extract, which has a direct financial interest in the product’s continued use), refined by the dose ranges used in modern controlled trials. Competing therapeutic approaches are presented below without framing one as the default.

  • Sexual function dose (men with mild-to-moderate erectile dysfunction): 250 mg three times daily (750 mg/day total) of a standardized extract (45–60% saponins), with meals, for 8–12 weeks. This is the dose range used in the majority of positive RCTs and meta-analyses for erectile function.

  • Sexual function dose (women, premenopausal and postmenopausal): 250–750 mg/day of standardized extract, divided into 1–3 doses with meals, for 8–16 weeks. Lower doses than the male erectile-function range have been used in most female sexual-function trials.

  • Glycemic / lipid dose (adults with type 2 diabetes or dyslipidemia): 1,000 mg/day of standardized extract for 3 months, as used in the Samani et al. (2016) RCT. This higher dose is supported by the metabolic-endpoint evidence specifically and should be weighed against the higher gastrointestinal side-effect rate at doses above standard.

  • Sport / male health profile dose: 750–1,500 mg/day used in various trials in physically active men. Despite widespread marketing, no compelling evidence supports an ergogenic (performance-enhancing) effect at these doses, and they are not justified by current evidence outside specific sexual-function or fertility indications.

  • Best time of day: Take with meals, divided into 2–3 daily doses (e.g., morning and evening, or morning, midday, and evening). The last dose should ideally be taken no later than early evening, since some users report sleep disturbance and elevated heart rate at higher doses.

  • Half-life: The pharmacokinetic half-life of protodioscin and its sapogenins has not been formally characterized in published human studies. The use of 2–3 daily divided doses across nearly all clinical trials suggests a relatively short effective duration, which supports split rather than single dosing.

  • Single vs. split dosing: Split dosing (2–3 times daily) is the approach used in the majority of clinical trials, supports more consistent plasma concentrations, and reduces gastrointestinal side effects compared to a single large daily dose.

  • Genetic polymorphisms: No pharmacogenomic guidance exists specifically for Tribulus terrestris. Adults known to be CYP3A4 poor metabolizers may experience higher exposure to both saponins and any co-administered CYP3A4 substrate drugs, but routine genotyping is not currently recommended.

  • Sex-based differences: Women — particularly postmenopausal women — appear to respond to lower doses (250–750 mg/day) for sexual function. Men with normal baseline testosterone are unlikely to experience hormonal changes at any dose; men with mild-to-moderate erectile dysfunction respond best at 750 mg/day.

  • Age-related considerations: Older adults (60+) may benefit more for erectile and overall sexual function but should start at the lower end of the dose range and monitor more carefully for drug interactions and orthostatic hypotension given the higher likelihood of polypharmacy and reduced organ reserve.

  • Baseline biomarker levels: Adults with low baseline testosterone (hypogonadal men) may experience modest hormonal changes that are absent in eugonadal men. Adults with diagnosed type 2 diabetes or dyslipidemia may experience metabolic benefits not seen in metabolically healthy users.

  • Pre-existing conditions: Adults with type 2 diabetes should monitor glucose closely and adjust medications under medical guidance. Adults with cardiovascular disease should be cautious about the hypotensive effect and the documented CYP3A4-statin interaction. Adults with infertility may benefit from a 750–1,500 mg/day course over 60–90 days under reproductive medicine supervision.

Discontinuation & Cycling

  • Lifelong vs. short-term: Tribulus terrestris is typically used in defined courses of 1–3 months in clinical trials rather than as an indefinite daily supplement. There is limited evidence on the safety or efficacy of continuous use beyond 3–6 months.

  • Withdrawal effects: No specific withdrawal effects have been documented in the clinical literature. Because Tribulus terrestris does not appear to meaningfully alter endogenous testosterone production in eugonadal users, rebound hormonal suppression on discontinuation is not expected.

  • Tapering: No tapering protocol is required based on current evidence. Supplementation can be stopped abruptly without adverse effect.

  • Cycling: Cycling is not formally established in clinical research, but many practitioners apply general herbal-supplement principles — for example, 8–12 weeks on, followed by 2–4 weeks off — to allow periodic reassessment, reduce any theoretical risk of cumulative organ exposure, and confirm that perceived benefits are durable rather than placebo-driven. This approach reflects practitioner convention rather than data specific to Tribulus terrestris.

Sourcing and Quality

  • Standardization: Look for fruit extracts standardized to 45–60% steroidal saponins, with protodioscin content specified separately when possible. Higher-saponin preparations (90–95%) exist and require proportionally lower doses but are less common in mainstream products.

  • Plant part: Fruit extracts are the most studied form for sexual-function indications and are preferred over root or aerial-part extracts. Root extracts have been more commonly used in traditional Ayurvedic preparations but lack the same level of supporting clinical data for the sexual-function and metabolic outcomes discussed above.

  • Geographical origin: Bulgarian, Turkish, and Indian sources are traditionally credited with higher protodioscin content. Standardization to a defined saponin and protodioscin percentage on the label is more reliable than origin claims alone.

  • Third-party testing — critically important: Independent product testing has repeatedly identified Tribulus terrestris supplements adulterated with undeclared anabolic steroids, synthetic testosterone, prohormones, or PDE5 inhibitors, particularly in products marketed for bodybuilding or male enhancement. Select products verified by NSF International (NSF Certified for Sport), USP (United States Pharmacopeia), or Informed Sport, especially for adults subject to anti-doping testing.

  • Reputable brands and preparations: Tribestan (Sopharma, the original Bulgarian standardized extract), Life Extension (standardized fruit extract from a longevity-focused brand), NOW Foods, Pure Encapsulations, and Double Wood Supplements are examples of producers that publish standardization data and conduct independent quality testing.

  • Contamination alert: Any product priced significantly below comparable standardized extracts, marketed primarily for bodybuilding or male enhancement, or making “natural anabolic” claims should be treated with skepticism and verified through certificate-of-analysis review or third-party testing.

Practical Considerations

  • Time to effect: Sexual-function improvements are typically reported after 4–12 weeks of consistent supplementation at 250–750 mg/day. Lipid and glycemic changes in trial settings have generally required 8–12 weeks. Trial designs allow at least 8 weeks before efficacy is assessed, and acute, single-dose effects are not observed.

  • Common pitfalls:
    • Expecting testosterone elevation: The most pervasive misconception is that Tribulus terrestris meaningfully raises testosterone in eugonadal men. Modern controlled trials and meta-analyses (Morgado et al., 2024) do not support this claim, and continuing to expect a testosterone effect is the single most common source of disappointment with the supplement.
    • Choosing untested products: Given the documented contamination rate, selecting products without third-party verification is a meaningful risk — particularly for athletes subject to anti-doping testing.
    • Excessive dosing: Some users escalate to doses well above 1,500 mg/day in pursuit of stronger effects, raising the rate of gastrointestinal side effects and potentially the risk of organ toxicity without proportionate benefit.
    • Ignoring drug interactions: The CYP3A4-statin interaction is underappreciated outside clinical pharmacy circles; adults on statins are at meaningful risk for rhabdomyolysis if this interaction is overlooked.
    • Confusing improvement in erection quality with testosterone change: Improvements in erectile function are mediated by nitric oxide release and do not require, or imply, a change in circulating testosterone.

  • Regulatory status: Tribulus terrestris is sold as a dietary supplement in the United States and is not subject to pre-market FDA (U.S. Food and Drug Administration) review for efficacy or safety. In some European countries (notably Bulgaria), the standardized Tribestan preparation is registered as a traditional or herbal medicinal product with specific labeling requirements. It is not a prescription medication anywhere it is commonly sold.

  • Cost and accessibility: Tribulus terrestris supplements are widely available and inexpensive, typically $10–30 USD for a 1–2 month supply. Third-party-tested and standardized products tend toward the higher end of this range; ultra-low-cost products are more likely to lack standardization or be adulterated.

Interaction with Foundational Habits

  • Sleep: The interaction with sleep is direct but variable. At standard doses (250–750 mg/day), controlled trials have not reported meaningful effects on sleep quality. At doses above 1,000 mg/day, anecdotal reports describe sleep disturbance, restlessness, and elevated resting heart rate in some users, possibly through mild sympathetic stimulation. Practical consideration: take the last daily dose no later than early evening, and reduce or split doses if sleep quality declines after initiation.

  • Nutrition: The interaction with nutrition is direct and potentiating in two senses — taking with meals improves absorption and substantially reduces gastrointestinal side effects, and the supplement’s lipid-lowering signal complements a Mediterranean-style or DASH (Dietary Approaches to Stop Hypertension, a dietary pattern emphasizing fruits, vegetables, whole grains, and limited sodium) eating pattern. No nutrient depletion has been documented. Practical consideration: take with food containing some fat; avoid empty-stomach dosing.

  • Exercise: The interaction with exercise is none for performance and modest at best for recovery. Despite its long-running use in sports-nutrition products, systematic reviews have consistently failed to show ergogenic effects on strength, power, endurance, or muscle mass; Tribulus terrestris does not blunt training adaptations either. Timing relative to workouts is not a meaningful consideration. Practical consideration: do not expect performance enhancement or hypertrophy support from this supplement.

  • Stress management: The interaction with stress management is indirect at most. No direct effect on cortisol or the HPA (hypothalamic-pituitary-adrenal, the body’s central stress-response system) axis has been documented in human studies. Some preclinical work suggests mild adaptogenic activity, but this has not translated to validated stress-response outcomes in controlled human trials. Practical consideration: treat Tribulus terrestris as a sexual-function and (in diabetic adults) metabolic support, not as a stress-modulating intervention.

Monitoring Protocol & Defining Success

Baseline labs and clinical parameters should be obtained before starting Tribulus terrestris to establish reference values for safety monitoring and efficacy assessment.

Ongoing monitoring follows the cadence: baseline, then 4–6 weeks after initiation (focused on liver and kidney function), then 8–12 weeks after initiation (full panel), then every 3–6 months during continued use. Sexual-function questionnaire scores can be reassessed at 8–12 weeks to determine response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT (alanine aminotransferase) < 25 U/L Detect early hepatic injury A liver enzyme released when liver cells are damaged. Conventional reference range up to 35–40 U/L; functional medicine practitioners use a tighter target. Fasting not required.
AST (aspartate aminotransferase) < 25 U/L Detect early hepatic injury A liver enzyme also elevated in muscle injury. Conventional reference range up to 35–40 U/L. Best paired with ALT.
Total bilirubin 0.2–1.0 mg/dL Baseline for hepatotoxicity monitoring Conventional range up to 1.2 mg/dL; physiologically elevated in Gilbert syndrome.
Creatinine 0.7–1.1 mg/dL (men); 0.6–1.0 mg/dL (women) Detect kidney impairment before and during use A muscle-derived waste product cleared by the kidneys. Conventional ranges similar; affected by muscle mass and hydration.
eGFR > 90 mL/min/1.73 m² Comprehensive kidney function assessment Estimated glomerular filtration rate, calculated from creatinine. Conventional threshold for normal > 60 mL/min/1.73 m².
BUN (blood urea nitrogen) 10–16 mg/dL Assess renal function and hydration Conventional range 7–20 mg/dL. Fasting preferred.
Fasting glucose 72–85 mg/dL Baseline metabolic health; track hypoglycemia risk Conventional range 70–100 mg/dL. Requires 8–12 hour fast.
HbA1c 4.8–5.2% Long-term glucose control baseline and follow-up Glycated hemoglobin reflects average glucose over 2–3 months. Conventional non-diabetic range below 5.7%. Fasting not required.
Total testosterone (men) 500–900 ng/dL Establish baseline hormonal status to confirm whether the user is hypogonadal Conventional reference range 264–916 ng/dL. Measure in the morning before 10 AM for accuracy.
Free testosterone (men) 9–25 pg/mL Assess bioavailable hormone Conventional reference varies by laboratory. Morning draw.
Total cholesterol < 200 mg/dL Baseline lipid status; track lipid response Conventional reference < 200 mg/dL. Fasting 9–12 hours preferred.
LDL cholesterol < 100 mg/dL Track lipid-lowering response LDL = low-density lipoprotein. Fasting preferred.
HDL cholesterol > 60 mg/dL Complete lipid assessment HDL = high-density lipoprotein. Conventional ranges > 40 mg/dL men, > 50 mg/dL women.
Blood pressure (home) < 120/80 mmHg Detect additive hypotension or unmasked hypertension Measure at rest, same time of day, validated cuff. Conventional target < 130/80 mmHg.
Resting heart rate (home) 50–70 bpm Detect cardiovascular stimulation at higher doses Measured at rest in the morning. Notable rise should prompt dose review.

Qualitative markers:

  • Sexual function and libido (using validated instruments such as the IIEF for men or the FSFI for women if seeking objective tracking)
  • Energy levels and overall sense of vitality
  • Gastrointestinal comfort and bowel habits
  • Sleep quality and morning rested feeling, particularly at higher doses
  • Any signs of hepatic injury (jaundice, dark urine, right-upper-quadrant pain, unusual fatigue)
  • Any signs of kidney injury (decreased urine output, lower-extremity swelling, fatigue)
  • Muscle pain or weakness if combined with statins (potential rhabdomyolysis warning sign)

Emerging Research

Several active and recent research directions are evaluating Tribulus terrestris across both directions — studies that could strengthen and studies that could weaken the case for the intervention.

  • Oligospermia phase 4 trial: A Phase 4, currently recruiting RCT (NCT06260007) evaluating the efficacy and safety of a Tribulus terrestris-based product in 204 men with oligospermia (low sperm count). This is one of the largest Tribulus terrestris trials to date and could provide more definitive evidence on the fertility benefit signal seen in earlier small trials, or weaken the case if the larger sample fails to confirm.

  • Broader phytopharmacological applications: A 2024 narrative review published in Heliyon surveyed Tribulus terrestris across multiple therapeutic directions — including immunomodulatory, cardioprotective, anti-inflammatory, antidiabetic, and hypolipidemic activities — and consolidated the case for further nutraceutical development in both human and veterinary settings (Saeed et al., 2024). If any of these directions translate into adequately powered human trials, novel application areas beyond sexual and metabolic health could open up.

  • Neuroprotection mechanism work: Preclinical work on tribulusterine, a constituent of Tribulus terrestris, demonstrated neuroprotective effects through attenuation of stress-kinase-mediated inflammatory signaling (Ranjithkumar et al., 2019). Validation in human trials would position Tribulus terrestris as a candidate for cognitive-health applications, but this evidence remains pre-clinical at present.

  • Female reproductive and menopausal health: Small, mainly preliminary trials are examining Tribulus terrestris for polycystic ovary syndrome and menopausal vasomotor symptoms beyond sexual-function endpoints. Larger and methodologically rigorous trials would be required to elevate any of these from speculative to medium evidence.

  • Standardization and pharmacokinetic characterization: Multiple research groups are working on validated assays for protodioscin and sapogenin pharmacokinetics in humans. Better characterization could clarify the apparent mismatch between traditional dosing recommendations and the inconsistent clinical effects observed across trials, and could identify whether specific saponin profiles correlate with stronger or weaker outcomes.

  • Head-to-head trials against PDE5 inhibitors: Adequately powered RCTs comparing Tribulus terrestris directly against PDE5 inhibitors (sildenafil, tadalafil) for erectile function would clarify the practical role of the supplement, building on the small placebo-controlled signal documented by Suharyani et al., 2026.

  • Testosterone-replacement comparison in hypogonadal men: Trials comparing Tribulus terrestris against testosterone-replacement therapy in hypogonadal men could resolve the unresolved hormonal-effect question raised by Vilar Neto et al., 2025 and Morgado et al., 2024.

  • Long-term safety studies: Long-term (>12 month) safety studies would address the gap in chronic-use data noted in the toxicological review by Ștefănescu et al., 2020.

Conclusion

Tribulus terrestris is a long-used herbal supplement whose modern evidence base diverges from its popular reputation. The strongest evidence — at a medium level of certainty — supports modest improvements in sexual function, both for men with mild-to-moderate erectile dysfunction and for women across reproductive stages, mediated through nitric oxide release rather than changes in circulating testosterone. The widely marketed claim that it raises testosterone in men with normal hormone levels is not supported by modern controlled trials.

Secondary benefits — improvements in lipid profile and glycemic control — appear primarily in adults with type 2 diabetes or dyslipidemia. The supplement is generally well tolerated at standard doses, though rare cases of serious liver and kidney injury, a documented interaction with certain cholesterol-lowering medications that has produced severe muscle breakdown, and a high rate of product contamination with undeclared steroids and prescription drugs recur in the safety literature.

A meaningful share of the foundational evidence and the most-studied standardized extract originate with a single commercial manufacturer (Sopharma’s Tribestan), and that financial interest sits alongside the independent literature. The most defensible application supported by the evidence is short-term sexual-function support, particularly in older men with erectile concerns and in postmenopausal women, with a third-party-verified standardized extract at conservative doses.

Top - Benefits - Risks - Protocol